X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (213) 213
Conference Proceeding (44) 44
Publication (40) 40
Book Review (10) 10
Book Chapter (3) 3
Manuscript (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (107) 107
humans (101) 101
oncology (101) 101
male (73) 73
female (72) 72
middle aged (62) 62
aged (50) 50
cancer (48) 48
adult (43) 43
carcinoma, renal cell - drug therapy (37) 37
metastasis (36) 36
kidney neoplasms - drug therapy (35) 35
kidney neoplasms - pathology (34) 34
survival (30) 30
carcinoma, renal cell (29) 29
care and treatment (28) 28
treatment outcome (28) 28
prognosis (27) 27
sunitinib (27) 27
disease-free survival (25) 25
antineoplastic agents - therapeutic use (24) 24
carcinoma, renal cell - mortality (22) 22
kidney neoplasms - mortality (22) 22
neoplasm metastasis (22) 22
carcinoma, renal cell - pathology (21) 21
carcinoma, renal cell - secondary (21) 21
interferon-alpha (21) 21
urology & nephrology (20) 20
aged, 80 and over (18) 18
retrospective studies (17) 17
survival analysis (17) 17
kidney cancer (16) 16
carcinoma (15) 15
indoles - therapeutic use (15) 15
patient outcomes (15) 15
pyrroles - therapeutic use (15) 15
risk factors (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
chemotherapy (14) 14
renal cell carcinoma (14) 14
sorafenib (14) 14
urology (14) 14
proportional hazards models (13) 13
research (13) 13
toxicity (13) 13
trial (13) 13
abridged index medicus (12) 12
analysis (12) 12
quality-of-life (12) 12
antineoplastic agents (11) 11
article (11) 11
chronotherapy (11) 11
everolimus (11) 11
fluorouracil - administration & dosage (11) 11
hematology, oncology and palliative medicine (11) 11
leucovorin - administration & dosage (11) 11
medicine & public health (11) 11
breast-cancer (10) 10
carcinoma, renal cell - genetics (10) 10
circadian (10) 10
circadian rhythm (10) 10
kaplan-meier estimate (10) 10
kidney neoplasms - genetics (10) 10
patients (10) 10
quality of life (10) 10
survival rate (10) 10
angiogenesis inhibitors - therapeutic use (9) 9
antimitotic agents (9) 9
clinical trials (9) 9
colorectal neoplasms - drug therapy (9) 9
colorectal neoplasms - pathology (9) 9
efficacy (9) 9
expression (9) 9
follow-up studies (9) 9
radiology, nuclear medicine & medical imaging (9) 9
targeted therapy (9) 9
therapy (9) 9
time factors (9) 9
vascular endothelial growth factor (9) 9
biomarkers, tumor - genetics (8) 8
databases, factual (8) 8
disease progression (8) 8
fatigue (8) 8
outcomes (8) 8
pathology (8) 8
phase-ii (8) 8
prospective studies (8) 8
renal-cell carcinoma (8) 8
reproducibility of results (8) 8
tumors (8) 8
animals (7) 7
cancer patients (7) 7
cardiac & cardiovascular systems (7) 7
colorectal cancer (7) 7
drug administration schedule (7) 7
kidney neoplasms (7) 7
molecular targeted therapy (7) 7
mortality (7) 7
neoplasm staging (7) 7
pazopanib (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Maturitas, ISSN 0378-5122, 06/2019, Volume 124, pp. 113 - 114
Journal Article
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 5599 - 5599
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1814 - 1823
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 8, pp. 760 - 767
Purpose This international phase III trial (Investigating Torisel As Second-Line Therapy [INTORSECT]) compared the efficacy of temsirolimus (mammalian target... 
SURVIVAL | INTERFERON-ALPHA | EVEROLIMUS | ONCOLOGY | BEVACIZUMAB | DOUBLE-BLIND | AGENTS | Niacinamide - analogs & derivatives | TOR Serine-Threonine Kinases - metabolism | Humans | Middle Aged | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | TOR Serine-Threonine Kinases - antagonists & inhibitors | Young Adult | Receptors, Vascular Endothelial Growth Factor - metabolism | Time Factors | Phenylurea Compounds - adverse effects | Treatment Failure | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Adult | Carcinoma, Renal Cell - enzymology | Female | Carcinoma, Renal Cell - drug therapy | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Kidney Neoplasms - mortality | Disease Progression | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - enzymology | Indoles - therapeutic use | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Index Medicus | ORIGINAL REPORTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 22, pp. 3584 - 3590
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 3, pp. 286 - 296
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 3, pp. 293 - 300
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 02/2017, Volume 35, Issue 6, pp. 458 - 458
Conference Proceeding
Circulation, ISSN 0009-7322, 11/2015, Volume 132, Issue Suppl_3 Suppl 3, pp. A17097 - A17097
BackgroundThe optimization of primary preventive cardiovascular (CV) strategies is urgently needed. The objective of the present study was to evaluate the... 
Journal Article